Sanofi India Stock Falls to 52-Week Low of Rs.4142.95 Amidst Prolonged Downtrend

Recent Price Movement and Market Context

On 17 Dec 2025, Sanofi India’s stock price touched Rs.4142.95, the lowest level recorded in the past 52 weeks. This decline comes after six consecutive trading sessions where the stock has recorded a cumulative return of -4.58%. The stock’s trading range today was relatively narrow, confined within Rs.38.9, reflecting subdued volatility amid the ongoing downtrend.

In comparison, the broader Pharmaceuticals & Biotechnology sector has outperformed Sanofi India, with the stock underperforming the sector by -0.72% on the day. The Sensex, India’s benchmark index, opened positively with a gain of 176.40 points but later reversed to close down by 235.11 points at 84,621.15, a marginal decline of -0.07%. Notably, the Sensex remains close to its 52-week high of 86,159.02, trading just 1.82% below that peak and maintaining a bullish stance above its 50-day and 200-day moving averages.

Technical Indicators and Moving Averages

Sanofi India’s share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning suggests a sustained bearish momentum in the short to long term. The stock’s inability to breach these technical resistance levels has contributed to the ongoing pressure on its price.

Long-Term Performance and Financial Metrics

Over the last year, Sanofi India’s stock has recorded a return of -32.96%, significantly lagging behind the Sensex’s 4.88% gain during the same period. The stock’s 52-week high was Rs.6717.5, indicating a substantial decline from that peak to the current low. This underperformance extends beyond the last year, with the stock also trailing the BSE500 index over the past three years and three months.

Financially, the company’s net sales have shown a negative compound annual growth rate of -8.47% over the past five years, while operating profit has reflected a similar trend with a -5.55% annual rate. The September 2025 quarter results were largely flat, offering little momentum to reverse the prevailing trend.

Balance Sheet Strength and Valuation

Despite the subdued top-line and operating performance, Sanofi India exhibits strong management efficiency, with a return on equity (ROE) of 49.40%. The company maintains a low average debt-to-equity ratio, effectively at zero, indicating a conservative capital structure. The price-to-book value stands at 12.3, which is considered attractive relative to its peers’ historical valuations.

Profitability has seen a slight contraction, with profits falling by -0.9% over the past year. However, the stock offers a dividend yield of 4.6% at the current price level, which is relatively high within the Pharmaceuticals & Biotechnology sector.

Shareholding and Institutional Interest

Institutional investors hold a significant stake in Sanofi India, accounting for 27.86% of the share capital. This level of institutional ownership suggests a degree of confidence in the company’s fundamentals from entities with extensive analytical resources.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Sanofi India’s recent price action contrasts with the broader market’s relative strength. While the Sensex trades near its 52-week high and maintains bullish moving averages, Sanofi India’s stock remains below all major moving averages, reflecting a divergence from the general market trend.

The sector itself has experienced mixed performance, but Sanofi India’s share price trajectory has been notably weaker, as evidenced by its underperformance relative to sector peers and benchmark indices.

Summary of Key Price and Performance Data

To summarise, Sanofi India’s stock has:

• Reached a 52-week low of Rs.4142.95 on 17 Dec 2025


• Recorded a six-day consecutive decline with a cumulative return of -4.58%


• Underperformed the Pharmaceuticals & Biotechnology sector by -0.72% on the latest trading day


• Traded below all major moving averages (5, 20, 50, 100, 200 days)


• Delivered a one-year return of -32.96%, compared to Sensex’s 4.88%


• Exhibited negative annual growth rates in net sales (-8.47%) and operating profit (-5.55%) over five years


• Maintained a high ROE of 49.40% and a low debt-to-equity ratio


• Offered a dividend yield of 4.6% at the current price


• Had institutional holdings of 27.86%

These factors collectively illustrate the challenges faced by Sanofi India’s stock in recent periods, as well as the financial and market context surrounding its current valuation and price levels.

Only ₹14,999 - Get MojoOne + Stock of the Week for 2 Years PLUS 6 Months FREE Claim 83% OFF →